Taiho Ventures, LLC — Full Portfolio

ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.

BiotechHealthtechSouth San Francisco, US

Richard Heyman(Chairman, Founder, Scientific Advisory Board)Charles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)Dominic Piscitelli(Chief Financial Officer)inPratik Multani(Chief Medical Officer)inJacob Chacko(President, Chief Executive Officer and Board Member)in

Co-investorsEcoR1 CapitalNew Enterprise Associates (NEA)Nextech InvestThe Column Group

Anavo Therapeutics is a biopharmaceutical company using its IGNITE platform to develop phosphatase-targeted allosteric modulators, addressing drug targets previously considered undruggable.

BiotechHealthtechLeiden, NL

Birgit Zech(CEO)in

Co-investorsBioqube VenturesInkefM Ventures

cellvie develops Therapeutic Mitochondria Transplantation technology and products for patients requiring mitochondrial treatment.

BiotechHealthtechLongevityMedical Devices

Co-investorsBeiersdorf Innovation Fund

Light Horse Therapeutics is a drug discovery company applying scientific expertise and innovation to advance healthcare through collaborative development.

AI & Machine LearningBiotechMedical Devices

Co-investorsAbbVieMubadala CapitalVersant Ventures

Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.

BiotechHealthtech

Rachel Humphrey(Founding Chief Executive Officer)Lieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)William LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)

Co-investorsSanofi VenturesPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut InnovationsPfizer Venture Investments+3 more

Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment.

BiotechHealthtech

Co-investorsEpidarex CapitalOxford Science EnterprisesSound BioventuresM Ventures

Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.

BiotechHealthtechMedical DevicesFoster City, US

Nenad Tomasevic(Executive Officer, Director)

BoardIvan Trifunovich(Director)John Wesley(Director)

Board seatSakae Asanuma· per SEC Form D

Co-investors8VCAisling CapitalMission Bay CapitalMission BiocapitalOlive Tree CapitalSR One Capital Management+1 more

BiotechBoston, US

Darlene Deptula-Hicks(Executive Officer)Rachel Humphrey(Officer and a Manager)Scott Phillips(Executive Officer)

BoardDavid Parry(Manager)Sara Nayeem(Manager)Timothy Shannon(Manager)

Board seatSakae Asanuma· per SEC Form D · $75M raise · filed Jan 2025

Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.

Biotech

Juan Jaen(Founder)in

Co-investorsAisling CapitalDecheng CapitalDroia VenturesEcoR1 CapitalForesite CapitalSLVC+2 more

Breakpoint Therapeutics develops cancer treatments based on modulating DNA damage response pathways.

BiotechMedical Devices

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in

BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in

Co-investorsMPM BioImpactPfizer Venture InvestmentsBiotechnology Value FundMirae Asset Venture InvestmentPfizer VenturesPolaris Partners

Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.

BiotechDigital Health

Co-investorsLAVLilly Asia VenturesMPM BioImpactSchooner Capital

Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies.

BiotechHealthtechCambridge, US

Kevin Marks(Founder)in

Co-investorsGV (Google Ventures)Nextech InvestAlexandria

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

Ann Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)

BoardSamuel Bjork(Director)Alexandra Cantley(Director)Seiji Miyahara(Director)

Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundRoche Venture FundSamsara BioCapital+3 more

BiotechMedical DevicesNew Haven, US

Scott Phillips(Executive Officer)in

BoardTim Shannon(Manager)inLiam Ratcliffe(Manager)in

Co-investorsAccess BiotechnologyCanaan PartnersConnecticut InnovationsFrazier Life SciencesRA CapitalVida Ventures

BiotechSouth San Francisco, US

Luke Nathaniel Walker(Executive Officer)Julie Eastland(Executive Officer, Director)

BoardRonald Hunt(Director)Mark Chin(Director)Alan Colowick(Director)Jonathan Drachman(Director)

Co-investorsK2 HealthVenturesArix BioscienceLilly Asia VenturesMPM BioImpactNew Leaf Venture PartnersOrbiMed

Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.

Cambridge, US

Leslie J Williams(Executive Officer, Director)

BoardBenjamin Chen(Director)Seiji Miyahara(Director)Sacha Mann(Director)David Moskowitz(Director)Steven Gillis(Director)in

Co-investorsARCH Venture Partners8VCTakeda Ventures

Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders.

AI & Machine LearningBiotechMedical Devices

Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)Michael Rosbash, PhD(Founder & Advisor)Richa Saxena, PhD(Founder & Advisor)Stuart Schreiber, PhD(Founder & Advisor)

Co-investorsARCH Venture PartnersNewpath Partners

Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications.

AI & Machine LearningBiotechMedical Devices

Joe Bolen(Chief Executive Officer)Joe Bolen, Ph.D.(Chief Executive Officer)Hope D'Oyley-Gay, JD(Chief Legal Officer)Ciaran Lawlor, Ph.D.(Chief Operating Officer)Frank Neumann, M.D., Ph.D.(Chief Medical Officer)Siva Sakhamuri(Chief Technology Officer)

Co-investorsAstellas Venture Management LLCMPM BioImpact

STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology.

BiotechHealthtechMedical Devices

Co-investorsFast Track InitiativeM VenturesPfizer Venture InvestmentsSeroba Life SciencesUTokyo Innovation Platform Co. Ltd.Cambridge Innovation Capital+1 more

Transition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease.

AI & Machine LearningBiotechDeep TechCambridge, US

Tuomas Knowles(Executive Director, Co-Founder & Chief Technology Officer)Samuel Cohen(Executive Director & Co-Founder)G. Kelly Martin(Executive Chairman & Co-Founder)George Martin(Executive Officer, Director)Stephanie Torruella(Executive Officer)Preet Makkar(Executive Officer)

Co-investorsNorthpond VenturesLifeforce CapitalMagnetic VenturesDolby Family Ventures

Vertero develops therapies for neurodegenerative diseases by targeting causative mechanisms in the peripheral nervous system rather than addressing symptoms alone.

BiotechHealthtechMedical Devices

Sarkis Mazmanian, PhD(Co-founder and Board Member)

Co-investorsUTokyo Innovation Platform Co. Ltd.

Co-investorsBreakout VenturesPfizer Venture Investments

Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.

BiotechHealthtechMedical DevicesWatertown, US

Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))inDaniel Hicklin(Executive Officer, Director)David Cordo(Executive Officer)Alon Lazarus(Director)

BoardChristoph Westphal(Director)

Co-investorsDC Investment PartnersK2 HealthVenturesLongwood FundMPM BioImpactRA Capital

LiberoThera is a drug discovery company using cell-free membrane protein preparation technology and non-natural amino acid incorporation technology to develop antibody-based therapeutics, including antibodies targeting GPCRs such as anti-CCR8.

BiotechDeep Tech

Co-investorsMC Healthcare VenturesUTokyo Innovation Platform Co. Ltd.